Nicox reported cash and cash equivalents of 36.3 million euros as of March 31 compared with 41.4 million euros at the end of 2017, according to a press release.
The company’s net revenue was 0.075 million euros in the first quarter of 2018, which was comprised entirely of royalty revenue from sales of Vyzulta (latanoprostene bunod ophthalmic solution 0.024%) through its partner Bausch + Lomb, after a deduction of royalty payments to Pfizer. Nicox recorded no revenue in the first quarter of 2017.
A new licensing agreement with Bausch + (Read more...)
Uncategorized